Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-788-6 | CAS number: 110-65-6
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
Expected to metabolize to 4-hydroxy-2-butynaldehyde (4-OH-butynal) and potentially further to 4-hydroxy-2-butyne-monocarboxylic acid and further yet to 2-butyne-1,4-dicarboxylic acid.
Short description of key information on absorption rate:
Dermal Absorption Rate (Estimated): 0.15 mg/cm2-hr.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
1,4 -Butynediol (B3D) is expected to metabolize to 4-hydroxy-2-butynaldehyde (4-OH-butynal) and potentially further to 4-hydroxy-2-butyne-monocarboxylic acid and further yet to 2-butyne-1,4-dicarboxylic acid. In addition, using U.S. EPA DERMWIN v1.43a, the dermal absorption rate of 1,4 -Butynediol is estimated to be 0.15 mg/cm2 -hr (ISP, 2010).
Discussion on bioaccumulation potential result:
It is proposed that 1,4 -Butynediol (B3D) is likely metabolized, via ADH, to 4-hydroxy-2-butynaldehyde (4-OH-butynal). Whether 4-OH-butynal is the ultimate toxicant is unknown. 4-OH-butynal could be further metabolized to its corresponding half acid, 4-hydroxy-2-butyne-monocarboxylic acid, via aldehyde dehydrogenase (ALDH). This 4-hydroxy-monoacid could potentially be further metabolized, via ADH and ALDH to the 2-butyne-1,4-dicarboxylic acid, following the general scheme attributed to many alkyl diols. Additionally, the B3D EU Risk Assessment Report (ECB, 2005) suggests that Cytochrome P450 dependent metabolism may also play a role in B3D conversion because a low increase in aminopyrine demethylase has been reported after B3D administration. The potential role of metabolism via glutathione has not been reported.
Discussion on absorption rate:
Using U.S. EPA DERMWIN v1.43a, the dermal absorption rate of 1,4 -Butynediol is estimated to be 0.15 mg/cm2 -hr (ISP, 2010). No measured data were available.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
